Zelavespib

• Description:

  Zelavespib (PU-H71) is a potent Hsp90 inhibitor, with an IC50 of 51 nM in MDA-MB-468 cells.

• Product Name Alternative:

  PU-H71

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  HSP

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/zelavespib.html

• Purity:

  99.93

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  CC (C) NCCCN1C (SC2=C (C=C3OCOC3=C2) I) =NC4=C (N=CN=C14) N

• Molecular Formula:

  C18H21IN6O2S

• Molecular Weight:

  512.37

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Caldas-Lopes E, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A. 2009 May 19;106 (20) :8368-73.|[2]Guo A, et al. HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment. Oncogene. 2017 Jun 15;36 (24) :3441-3449.|[3]Qu Z, et al. PU-H71 effectively induces degradation of IκB kinase β in the presence of TNF-α. Mol Cell Biochem. 2014 Jan;386 (1-2) :135-42.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• Isoform:

  HSP90

• CAS Number:

  873436-91-0